A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.

Transl Neurodegener · 2023 · PMC10652426 · PMID 37968718

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A decreasing trend or statistically significant attenuation of the plasma levels of macrophage/microglial activation chemokines C–C motif ligand (CCL)-2, CCL4 and CCL11 (Fig. 1 f–h) was also noted following IL-2 administration.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.